173 related articles for article (PubMed ID: 24897288)
1. LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Zhou PR; Liu HJ; Liao EY; Zhang ZL; Chen DC; Liu J; Wu W; Xing XP; Xia WB; Xu L; Li M
Pharmacogenomics; 2014 Apr; 15(6):821-31. PubMed ID: 24897288
[TBL] [Abstract][Full Text] [Related]
2. SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.
Zhou PR; Xu XJ; Zhang ZL; Liao EY; Chen DC; Liu J; Wu W; Jiang Y; Wang O; Xia WB; Xing XP; Xu L; Li M
Pharmacogenomics; 2015; 16(10):1077-88. PubMed ID: 26250343
[TBL] [Abstract][Full Text] [Related]
3. LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
Kruk M; Ralston SH; Albagha OM
Calcif Tissue Int; 2009 Mar; 84(3):171-9. PubMed ID: 19148563
[TBL] [Abstract][Full Text] [Related]
4. Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women.
Markatseli AE; Hatzi E; Bouba I; Georgiou I; Challa A; Tigas S; Tsatsoulis A
Maturitas; 2011 Oct; 70(2):188-93. PubMed ID: 21840657
[TBL] [Abstract][Full Text] [Related]
5. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of LRP5, but not of TNFRSF11B, is associated with a decrease in bone mineral density in postmenopausal Maya-Mestizo women.
Canto-Cetina T; Polanco Reyes L; González Herrera L; Rojano-Mejía D; Coral-Vázquez RM; Coronel A; Canto P
Am J Hum Biol; 2013; 25(6):713-8. PubMed ID: 24130145
[TBL] [Abstract][Full Text] [Related]
7. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
[TBL] [Abstract][Full Text] [Related]
8. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
9. Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Liu Y; Liu H; Li M; Zhou P; Xing X; Xia W; Zhang Z; Liao E; Chen D; Liu J; Tao T; Wu W; Xu L
Chin Med J (Engl); 2014; 127(4):662-8. PubMed ID: 24534219
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.
Wang C; Zheng H; He JW; Zhang H; Yue H; Hu WW; Gu JM; Shao C; Fu WZ; Hu YQ; Li M; Liu YJ; Zhang ZL
Pharmacogenomics J; 2015 Apr; 15(2):158-64. PubMed ID: 25223561
[TBL] [Abstract][Full Text] [Related]
11. A Study of the Relationship between the Polymorphism and Mutation of rs682429 and rs3781590 in the LRP5 Gene and Bone Metabolism in Postmenopausal Type 2 Diabetic Women in Xinjiang.
Li J; Li S; Zhao H; Li J; Wang S; Shi Y
J Diabetes Res; 2020; 2020():3071217. PubMed ID: 32405501
[TBL] [Abstract][Full Text] [Related]
12. Association of polymorphisms in low-density lipoprotein receptor-related protein 5 gene with bone mineral density in postmenopausal Chinese women.
Zhang ZL; Qin YJ; He JW; Huang QR; Li M; Hu YQ; Liu YJ
Acta Pharmacol Sin; 2005 Sep; 26(9):1111-6. PubMed ID: 16115379
[TBL] [Abstract][Full Text] [Related]
13. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
14. The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women.
Mondockova V; Adamkovicova M; Lukacova M; Grosskopf B; Babosova R; Galbavy D; Martiniakova M; Omelka R
BMC Med Genet; 2018 Sep; 19(1):174. PubMed ID: 30241506
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
16. Associations of LRP5 Gene With Bone Mineral Density, Bone Turnover Markers, and Fractures in the Elderly With Osteoporosis.
Wang QF; Bi HS; Qin ZL; Wang P; Nie FF; Zhang GW
Front Endocrinol (Lausanne); 2020; 11():571549. PubMed ID: 33101205
[No Abstract] [Full Text] [Related]
17. Low density lipoprotein receptor-related protein 5 gene polymorphisms and osteoporosis in Thai menopausal women.
Kitjaroentham A; Hananantachai H; Phonrat B; Preutthipan S; Tungtrongchitr R
J Negat Results Biomed; 2016 Sep; 15(1):16. PubMed ID: 27582019
[TBL] [Abstract][Full Text] [Related]
18. Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women.
Han LW; Ma DD; Xu XJ; Lü F; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Li M
Chin Med Sci J; 2016 Mar; 31(1):8-16. PubMed ID: 28031082
[TBL] [Abstract][Full Text] [Related]
19. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
20. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
Uchida K; Nakajima H; Miyazaki T; Yayama T; Kawahara H; Kobayashi S; Tsuchida T; Okazawa H; Fujibayashi Y; Baba H
J Nucl Med; 2009 Nov; 50(11):1808-14. PubMed ID: 19837766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
